Collagen Antibody-Induced Arthritis (CAIA) Model
- Background
- Models
- Study Examples
- Features
- FAQ
Creative Bioarray offers the Collagen Antibody Induced Arthritis (CAIA) Model, Collagen Induced Arthritis (CIA), Adjuvant Induced Arthritis (AIA) and various other RA disease models. Our services for these models encompass efficacy assessments, mechanistic investigations, biomarker analysis, and PK/PD studies, all designed to guide drug development choices for new small molecules, biologics, and immunotherapies, conducted within our CRO framework.
We offer both standard and tailored screening programs, complete with clinical scoring, histopathology, biochemical analyses, cytokine profiling, and adaptable subgroup designs to aid translational research.
Rheumatoid Arthritis (RA) Epidemiology & Disease Mechanism
Rheumatoid arthritis (RA) is a chronic autoimmune disease that impacts approximately 0.46 % (~460 out of 100,000) of the world's population with the disease predominately appearing in women and elderly individuals. Patients typically present with inflammation of the joints synovium, destruction of cartilage and ankylosis of the joints leading to eventual disability. Environmental cues and genetic predispositions promote dysregulated immune cell activation, antibody production and chronic production of pro‑inflammatory cytokines including TNF‑α, IL‑1 and IL‑6. Together, these factors lead to synovial hyperplasia, pannus development and osteoclast activation leading to bone degradation.
Current treatment options such as NSAIDs, DMARDs and biologic therapies treat symptoms and decrease inflammation for most RA patients; however, there are often cases where progression of disease is not stopped and immune dysregulation is not addressed. It is crucial that in vivo RA animal models mimic this disease progression in order to properly test drug efficacy, determine mechanism of action and support translational studies.
Fig. 1. Pathological mechanisms of rheumatoid arthritis (Guo Q, Wang Y, et al., 2018).
Creative Bioarray's CAIA Model
CAIA model is an antibody‑induced arthritis model that is initiated by injecting animals with a cocktail of preformed antibodies against type II collagen. Lipopolysaccharide (LPS) is then administrated to activate innate immune cells and induce joint inflammation.
Intraperitoneal injection of anti‑CII antibodies + LPS induces a synchronized onset of joint inflammation within ~48 h and peak disease by ~8 days, making CAIA ideal for time‑efficient efficacy assessment without the need for adjuvant sensitization.
Animal Strains
- C57BL/6 or Balb/c mouse
Endpoints
- Clinical arthritis scoring (paw swelling & thickness)
- Histopathology (HE, cartilage evaluation)
- Cytokine profiling and Biomarker analysis (ELISA/ WB)
- Body weight and functional measurements
Study Examples
Multi-Modal Outcome Assessment
Fig. 2. Representative clinical, imaging, and histological readouts of CAIA, including arthritis scoring, μCT bone analysis, and joint histopathology (Maleitzke T, Weber J, et al. 2022).
Clinical Arthritis Score & Paw Swelling
Fig. 2. CAIA induction leads to a significant increase in clinical arthritis score (reflecting paw inflammation and swelling) compared to control animals (Macáková K, Borbélyová V, et al., 2024).
Why Choose Creative Bioarray for RA Model Services
Extensive Disease Model Portfolio
Over 200+ validated in vivo disease models, including CAIA, CIA, and AIA, allowing you to select the most relevant RA model for your preclinical drug discovery and efficacy evaluation.
Rapid and Reproducible CAIA Induction
Our CAIA model uses a standardized anti-type II collagen antibody + LPS protocol, enabling consistent onset within 48 h and peak disease by day 8, which accelerates study timelines and reduces variability.
Comprehensive Endpoint Assessment
We integrate clinical scoring, paw swelling, histopathology, cytokine profiling, and biomarker analysis to provide multi-dimensional evidence of drug efficacy. This ensures data is translatable to human RA pathophysiology.
Customizable Study Design
Flexible grouping strategies (control, disease, multiple treatment doses), dosing regimens, and endpoint selection are tailored to your therapeutic mechanism of interest, including small molecules, biologics, and immune modulators.
FAQ
What makes the CAIA model advantageous compared to CIA or AIA?
CAIA allows rapid onset of arthritis (48 h) and peak inflammation in ~8 days, whereas CIA requires longer sensitization periods. It works across multiple mouse strains, including those not responsive to CIA, and provides robust clinical, pathological, and biochemical endpoints suitable for drug efficacy evaluation and mechanism studies.
Which endpoints are typically measured in CAIA studies?
Key endpoints include:
- Clinical scoring: paw swelling, redness, joint involvement
- Histopathology: synovial inflammation, cartilage erosion, bone loss (HE, Safranin O, TRAP staining)
- Biochemical markers: TNF‑α, IL‑1β, IL‑6, and other cytokines measured via ELISA
- Functional metrics: mobility, body weight, joint flexibility
This multi-dimensional readout ensures comprehensive assessment of drug effects.
Can the CAIA model evaluate both prophylactic and therapeutic interventions?
Yes. Our flexible study design allows administration of investigational compounds before disease induction (prophylactic) or after onset of inflammation (therapeutic). This helps assess prevention, disease modification, or symptomatic relief.
Are multiple mouse strains supported for CAIA studies?
Absolutely. We support C57BL/6, BALB/c, and other strains, including those less sensitive to CIA, enabling selection of the most appropriate translational model for your drug candidate.
Call to Action — Start Your In Vivo RA Program
Ready to accelerate your drug discovery and development with high fidelity in vivo drug efficacy evaluation? Contact Creative Bioarray to design a custom CAIA model study that fits your therapeutic goals and unlocks translational insights.
References
- Guo, Q., Wang, Y., et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018. 6, 15
- Macáková K, Borbélyová V, et al. Effects of exogenous deoxyribonuclease I in collagen antibody-induced arthritis. J Inflamm (Lond). 2024. 21(1):36.
- Maleitzke T, Weber J, et al. Standardized protocol and outcome measurements for the collagen antibody-induced arthritis mouse model. STAR Protoc. 2022. 3(4):101718.